Edition:
United Kingdom

Kyowa Hakko Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

2,164JPY
17 Nov 2017
Change (% chg)

¥-9 (-0.41%)
Prev Close
¥2,173
Open
¥2,200
Day's High
¥2,227
Day's Low
¥2,152
Volume
1,817,700
Avg. Vol
1,171,528
52-wk High
¥2,227
52-wk Low
¥1,512

Select another date:

Wed, Nov 1 2017

BRIEF-Ultragenyx and Kyowa Hakko Kirin announce FDA not currently planning to hold advisory committee meeting for Burosumab biologics license application

* Ultragenyx and Kyowa Hakko Kirin announce FDA not currently planning to hold advisory committee meeting for Burosumab biologics license application

BRIEF-Kyowa Hakko Kirin says voluntary adoption of International Financial Reporting Standards (IFRS)

* Says it plans to adopt International Financial Reporting Standards (IFRS) as the new accounting method, to replace the Japanese Generally Accepted Accounting Principles

BRIEF-ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION

* ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE AND PRIORITY REVIEW DESIGNATION OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION

BRIEF- Kyowa Hakko Kirin to sell part of stake in unit Kyowa Medex

* Says it will sell a part of stake in wholly owned unit Kyowa Medex Co., Ltd., to Hitachi Chemical Company, Ltd.

BRIEF- R&I affirms Kyowa Hakko Kirin's rating at "A+" and announces stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I

BRIEF-Ultragenyx, Kyowa Hakko Kirin announce submission of Burosumab's Biologics License Application in U.S.

* Ultragenyx and Kyowa Hakko Kirin announce submission of Burosumab's Biologics License Application in the U.S.

BRIEF-Sumitomo Chemical buys Kyowa Hakko's agrochemical segment - Nikkei

* Sumitomo Chemical Co Ltd to buy Kyowa Hakko Kirin's agrochemical segment in deal valued at 6 billion yen to 7 billion yen

Select another date: